Hercules Provides $75MM Facility to Mesoblast

Cell-based medicine developer Mesoblast entered into a $75 million non-dilutive, four-year credit facility with specialty finance company Hercules Capital.

Hercules Provides $75MM Sorrento Therapeutics Facility

Sorrento Therapeutics, a clinical-stage biopharmaceutical company developing treatments for cancer and other diseases, entered into a loan and security agreement with Hercules Capital for up to $75 million.